Search

Displaying results 1791 - 1800 of 10000 in total
  1. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  2. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. … It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.

  3. Drug

    Ferrous fumarate

    go.drugbank.com/drugs/DB14491
    ApprovedInvestigational

    Used in treatment of iron deficiency anemia.

    Mixtures: Vc II, Iron II
  4. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … Completion of this clinical trial is anticipated in early 2023.[L30240]

  5. Pathway

    Norgestrel Action Pathway

    smpdb.ca/view/SMP0126522
    Drug action

    This drug is used in combination with ethinyl estradiol for oral contraception and prevention of pregnancy in women.

    Drugs: NADH · ATP · Progesterone · Testosterone · Estrone · Potassium cation +9 more
    Enzymes: Estradiol 17-beta-dehydrogenase 1, Androgen receptor
  6. Pathway

    Drospirenone Action Pathway

    smpdb.ca/view/SMP0126538
    Drug action

    This helps to oppose the effects of naturally occurring androgens, inhibiting the binding of dihydrotestosterone (DHT) to its receptor, and preventing androgen synthesis in the ovaries, helping to treat

    Drugs: NADH · ATP · Progesterone · Testosterone · Estrone · Potassium cation +9 more
    Enzymes: Estradiol 17-beta-dehydrogenase 1, Androgen receptor
  7. Pathway

    Dienogest Action Pathway

    smpdb.ca/view/SMP0126541
    Drug action

    Dienogest acts by binding as an agonist to the progesterone receptor with weak affinity but high specificity. … Also, since this drug is an agonist of the androgen receptor, it helps to improve androgenic symptoms like acne and hirsutism. This drug is administered as an oral tablet.

    Drugs: NADH · ATP · Progesterone · Testosterone · Estrone · Potassium cation +9 more
    Enzymes: Estradiol 17-beta-dehydrogenase 1, Androgen receptor
  8. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol … Gout is closely associated with hyperuricemia. Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels.

  9. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea. … It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier.

  10. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.